Skip to main navigation
Iovance Biotherapeutics
  • About
    • About Iovance Biotherapeutics
    • Management
    • Board of Directors
    • Research Partners
  • Our Technology
    • About TIL
    • Publication and Scientific Presentations
  • Clinical
    • Clinical Program
      • Metastatic Melanoma
      • Cervical Carcinoma
      • Non-Small Cell Lung Cancer
      • Solid Tumors
      • Blood Cancers
    • Clinical Pipeline
    • Unmet Medical Need
    • Expanded Access Policy
  • Investors
    • Investor Overview
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Ownership Summary
      • Analyst Coverage
    • News & Events
      • Press Releases
      • Events & Presentations
    • Financial Information
      • SEC Filings
      • Financial Reports
      • Quarterly Results
      • Earnings Estimates
    • Fundamentals
      • Snapshot
      • Trading Statistics
      • Balance Sheet
      • Income Statement
      • Cash Flow
      • Ratios
    • Corporate Governance
      • Governance Highlights
      • Committee Composition
    • Investor Resources
      • Information Request
      • E-mail Alerts
      • IR Contacts
  • Careers
    • Why Iovance?
    • Current Job Openings
  • Patients
  • News
  • Contact

About Lion Biotech

Home Investors Node

Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During American Association for Cancer Research (AACR) 2021 Annual Meeting

  • Read more about Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During American Association for Cancer Research (AACR) 2021 Annual Meeting

Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer

  • Read more about Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer

Iovance Biotherapeutics to Present Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at American Association for Cancer Research (AACR) 2021 Annual Meeting

  • Read more about Iovance Biotherapeutics to Present Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at American Association for Cancer Research (AACR) 2021 Annual Meeting

Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences

  • Read more about Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates

  • Read more about Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates

Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25, 2021

  • Read more about Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25, 2021

Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences

  • Read more about Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences

Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021

  • Read more about Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021

Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer

  • Read more about Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer

Iovance Biotherapeutics to Present at Upcoming Conferences in December

  • Read more about Iovance Biotherapeutics to Present at Upcoming Conferences in December

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
  • Investor Toolkit
  • Print Page
  • RSS
  • E-mail Alerts
  • Home
    • hidden
  • About
  • Our Technology
  • Clinical
  • Investors
  • Careers

© 2021 Iovance Biotherapeutics, Inc All Rights Reserved.

  • Privacy Policy
  • Disclaimer
  • Sitemap